Cargando…
The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells
Myelodysplastic syndromes (MDS) are a heterogeneous, clonal haematopoietic disorder, with ~1/3 of patients progressing to acute myeloid leukaemia (AML). Many elderly MDS patients do not tolerate intensive therapeutic regimens, and therefore have an unmet need for better tolerated therapies. Epigenet...
Autores principales: | Clarke, Kathryn, Young, Christine, Liberante, Fabio, McMullin, Mary-Frances, Thompson, Alexander, Mills, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544403/ https://www.ncbi.nlm.nih.gov/pubmed/31191819 http://dx.doi.org/10.18632/oncotarget.26877 |
Ejemplares similares
-
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015) -
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016) -
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
por: Conforti, Franco, et al.
Publicado: (2017) -
Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin
por: Saraiva, Raúl G., et al.
Publicado: (2018) -
The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
por: Paillas, Salome, et al.
Publicado: (2020)